{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:36:03Z","timestamp":1790444163531,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1U01NS122102-01A1"],"award-info":[{"award-number":["1U01NS122102-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS123556-01A1"],"award-info":[{"award-number":["1R01NS123556-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5R01GM141296"],"award-info":[{"award-number":["5R01GM141296"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA602798"],"award-info":[{"award-number":["MDA602798"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"Amyotrophic Lateral Sclerosis Association","doi-asserted-by":"publisher","award":["20-IIP-516"],"award-info":[{"award-number":["20-IIP-516"]}],"id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An abnormal expansion of a GGGGCC (G\n                    <jats:sub>4<\/jats:sub>\n                    C\n                    <jats:sub>2<\/jats:sub>\n                    ) hexanucleotide repeat in the\n                    <jats:italic>C9ORF72<\/jats:italic>\n                    gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two debilitating neurodegenerative disorders driven in part by gain-of-function mechanisms involving transcribed forms of the repeat expansion. By utilizing a Cas13 variant with reduced collateral effects, we develop here a high-fidelity RNA-targeting CRISPR-based system for C9ORF72-linked ALS\/FTD. When delivered to the brain of a transgenic rodent model, this Cas13-based platform curbed the expression of the G\n                    <jats:sub>4<\/jats:sub>\n                    C\n                    <jats:sub>2<\/jats:sub>\n                    repeat-containing RNA without affecting normal C9ORF72 levels, which in turn decreased the formation of RNA foci, reduced the production of a dipeptide repeat protein, and reversed transcriptional deficits. This high-fidelity system possessed improved transcriptome-wide specificity compared to its native form and mediated targeting in motor neuron-like cells derived from a patient with ALS. These results lay the foundation for the implementation of RNA-targeting CRISPR technologies for C9ORF72-linked ALS\/FTD.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-55548-5","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:05:32Z","timestamp":1736312732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS\/FTD"],"prefix":"10.1038","volume":"16","author":[{"given":"Tristan X.","family":"McCallister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin K. W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najah S.","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Terpstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3269-3081","authenticated-orcid":false,"given":"Alisha Y.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-2909","authenticated-orcid":false,"given":"M. Alejandra","family":"Zeballos C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson E.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-8311","authenticated-orcid":false,"given":"Jenny","family":"Drnevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-9664","authenticated-orcid":false,"given":"Thomas","family":"Gaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"55548_CR1","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","volume":"344","author":"LP Rowland","year":"2001","unstructured":"Rowland, L. P. & Shneider, N. A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688\u20131700 (2001).","journal-title":"N. Engl. J. Med."},{"key":"55548_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/17482968.2011.639376","volume":"13","author":"P Lillo","year":"2012","unstructured":"Lillo, P., Savage, S., Mioshi, E., Kiernan, M. C. & Hodges, J. R. Amyotrophic lateral sclerosis and frontotemporal dementia: a behavioural and cognitive continuum. Amyotroph. Lateral Scler. 13, 102\u2013109 (2012).","journal-title":"Amyotroph. Lateral Scler."},{"key":"55548_CR3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/WNL.59.7.1077","volume":"59","author":"C Lomen-Hoerth","year":"2002","unstructured":"Lomen-Hoerth, C., Anderson, T. & Miller, B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59, 1077\u20131079 (2002).","journal-title":"Neurology"},{"key":"55548_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","volume":"65","author":"GM Ringholz","year":"2005","unstructured":"Ringholz, G. M. et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65, 586\u2013590 (2005).","journal-title":"Neurology"},{"key":"55548_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000112894","volume":"38","author":"F Pasquier","year":"2007","unstructured":"Pasquier, F. & Petit, H. Frontotemporal dementia: its rediscovery. Eur. Neurol. 38, 1\u20136 (2007).","journal-title":"Eur. Neurol."},{"key":"55548_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/nmt.14.34","volume":"4","author":"NT Bott","year":"2014","unstructured":"Bott, N. T., Radke, A., Stephens, M. L. & Kramer, J. H. Frontotemporal dementia: diagnosis, deficits and management. Neurodegener. Dis. Manag. 4, 439\u2013454 (2014).","journal-title":"Neurodegener. Dis. Manag."},{"key":"55548_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257\u2013268 (2011).","journal-title":"Neuron"},{"key":"55548_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"55548_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.4490","volume":"24","author":"Y Shi","year":"2018","unstructured":"Shi, Y. et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons. Nat. Med. 24, 313\u2013325 (2018).","journal-title":"Nat. Med."},{"key":"55548_CR10","doi-asserted-by":"crossref","unstructured":"Smeyers, J., Banchi, E.-G. & Latouche, M. C9ORF72: what it is, what it does, and why it matters. Front. Cell Neurosci. 15, 661447 (2021).","DOI":"10.3389\/fncel.2021.661447"},{"key":"55548_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00401-013-1199-1","volume":"126","author":"VV Belzil","year":"2013","unstructured":"Belzil, V. V. et al. Reduced C9ORF72 gene expression in C9FTD\/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 126, 895\u2013905 (2013).","journal-title":"Acta Neuropathol."},{"key":"55548_CR12","doi-asserted-by":"publisher","first-page":"7778","DOI":"10.1073\/pnas.1219643110","volume":"110","author":"Z Xu","year":"2013","unstructured":"Xu, Z. et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl Acad. Sci. USA 110, 7778\u20137783 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55548_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-016-0306-7","volume":"4","author":"P Rizzu","year":"2016","unstructured":"Rizzu, P. et al. C9ORF72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9ORF72, MAPT and GRN mutation carriers. Acta Neuropathol. Commun. 4, 37 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"55548_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-013-1192-8","volume":"126","author":"TF Gendron","year":"2013","unstructured":"Gendron, T. F. et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in C9FTD\/ALS. Acta Neuropathol. 126, 829\u2013844 (2013).","journal-title":"Acta Neuropathol."},{"key":"55548_CR15","doi-asserted-by":"publisher","first-page":"E4968","DOI":"10.1073\/pnas.1315438110","volume":"110","author":"T Zu","year":"2013","unstructured":"Zu, T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968\u2013E4977 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55548_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature14973","volume":"525","author":"K Zhang","year":"2015","unstructured":"Zhang, K. et al. The C9ORF72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56\u201361 (2015).","journal-title":"Nature"},{"key":"55548_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/nn.4085","volume":"18","author":"A Jovi\u010di\u0107","year":"2015","unstructured":"Jovi\u010di\u0107, A. et al. Modifiers of C9ORF72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD\/ALS. Nat. Neurosci. 18, 1226\u20131229 (2015).","journal-title":"Nat. Neurosci."},{"key":"55548_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature14974","volume":"525","author":"BD Freibaum","year":"2015","unstructured":"Freibaum, B. D. et al. GGGGCC repeat expansion in C9ORF72 compromises nucleocytoplasmic transport. Nature 525, 129\u2013133 (2015).","journal-title":"Nature"},{"key":"55548_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","volume":"77","author":"PeterEA Ash","year":"2013","unstructured":"Ash, PeterE. A. et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to C9FTD\/ALS. Neuron 77, 639\u2013646 (2013).","journal-title":"Neuron"},{"key":"55548_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1073\/pnas.1013343108","volume":"108","author":"T Zu","year":"2011","unstructured":"Zu, T. et al. Non-ATG\u2013initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA 108, 260\u2013265 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55548_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.1232927","volume":"339","author":"K Mori","year":"2013","unstructured":"Mori, K. et al. The C9ORF72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS. Science 339, 1335\u20131338 (2013).","journal-title":"Science"},{"key":"55548_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00401-013-1189-3","volume":"126","author":"K Mori","year":"2013","unstructured":"Mori, K. et al. Bidirectional transcripts of the expanded C9ORF72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881\u2013893 (2013).","journal-title":"Acta Neuropathol."},{"key":"55548_CR23","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41591-018-0071-1","volume":"24","author":"Y-J Zhang","year":"2018","unstructured":"Zhang, Y.-J. et al. Poly(GR) impairs protein translation and stress granule dynamics in C9ORF72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 24, 1136\u20131142 (2018).","journal-title":"Nat. Med."},{"key":"55548_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-018-1946-4","volume":"137","author":"TG Moens","year":"2019","unstructured":"Moens, T. G. et al. C9ORF72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 137, 487\u2013500 (2019).","journal-title":"Acta Neuropathol."},{"key":"55548_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","volume":"14","author":"R Martier","year":"2019","unstructured":"Martier, R. et al. Artificial microRNAs targeting C9ORF72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol. Ther. Nucleic Acids 14, 593\u2013608 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"55548_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","volume":"16","author":"R Martier","year":"2019","unstructured":"Martier, R. et al. Targeting RNA-mediated toxicity in C9ORF72 ALS and\/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids 16, 26\u201337 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"55548_CR27","doi-asserted-by":"publisher","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"110","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9ORF72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530\u2013E4539 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55548_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/nat.2016.0655","volume":"27","author":"J Hu","year":"2017","unstructured":"Hu, J., Rigo, F., Prakash, T. P. & Corey, D. R. Recognition of C9ORF72 mutant RNA by single-stranded silencing RNAs. Nucleic Acid Ther. 27, 87\u201394 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"55548_CR29","doi-asserted-by":"crossref","unstructured":"Cabrera, G. T. et al. Artificial microRNA suppresses C9ORF72 variants and decreases toxic dipeptide repeat proteins in vivo. Gene Ther. 31, 105\u2013118 (2023).","DOI":"10.1038\/s41434-023-00418-w"},{"key":"55548_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran, H. et al. Suppression of mutant C9ORF72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 28, 117\u2013124 (2022).","journal-title":"Nat. Med."},{"key":"55548_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535\u2013550 (2016).","journal-title":"Neuron"},{"key":"55548_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21112-8","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Variant-selective stereopure oligonucleotides protect against pathologies associated with C9ORF72-repeat expansion in preclinical models. Nat. Commun. 12, 847 (2021).","journal-title":"Nat. Commun."},{"key":"55548_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","volume":"173","author":"S Konermann","year":"2018","unstructured":"Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665\u2013676.e614 (2018).","journal-title":"Cell"},{"key":"55548_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh, O. O. et al. RNA targeting with CRISPR\u2013Cas13. Nature 550, 280\u2013284 (2017).","journal-title":"Nature"},{"key":"55548_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.molcel.2018.09.018","volume":"72","author":"MP Terns","year":"2018","unstructured":"Terns, M. P. CRISPR-based technologies: impact of RNA-targeting systems. Mol. Cell 72, 404\u2013412 (2018).","journal-title":"Mol. Cell"},{"key":"55548_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019\u20131027 (2017).","journal-title":"Science"},{"key":"55548_CR37","doi-asserted-by":"publisher","first-page":"eabk2485","DOI":"10.1126\/sciadv.abk2485","volume":"8","author":"JE Powell","year":"2022","unstructured":"Powell, J. E. et al. Targeted gene silencing in the nervous system with CRISPR-Cas13. Sci. Adv. 8, eabk2485 (2022).","journal-title":"Sci. Adv."},{"key":"55548_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","volume":"26","author":"KH Morelli","year":"2023","unstructured":"Morelli, K. H. et al. An RNA-targeting CRISPR\u2013Cas13d system alleviates disease-related phenotypes in Huntington\u2019s disease models. Nat. Neurosci. 26, 27\u201338 (2023).","journal-title":"Nat. Neurosci."},{"key":"55548_CR39","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1093\/nar\/gkac037","volume":"50","author":"P Kandasamy","year":"2022","unstructured":"Kandasamy, P. et al. Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS. Nucleic Acids Res. 50, 5401\u20135423 (2022).","journal-title":"Nucleic Acids Res."},{"key":"55548_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42147-z","volume":"14","author":"CMA Zeballos","year":"2023","unstructured":"Zeballos, C. M. A. et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat. Commun. 14, 6492 (2023).","journal-title":"Nat. Commun."},{"key":"55548_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","volume":"14","author":"R Balendra","year":"2018","unstructured":"Balendra, R. & Isaacs, A. M. C9ORF72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 14, 544\u2013558 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"55548_CR42","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neuron.2015.09.015","volume":"87","author":"H Tran","year":"2015","unstructured":"Tran, H. et al. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a drosophila model of C9ORF72 FTD\/ALS. Neuron 87, 1207\u20131214 (2015).","journal-title":"Neuron"},{"key":"55548_CR43","doi-asserted-by":"publisher","first-page":"1779.e1775","DOI":"10.1016\/j.neurobiolaging.2014.01.016","volume":"35","author":"AJ Waite","year":"2014","unstructured":"Waite, A. J. et al. Reduced C9ORF72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging 35, 1779.e1775\u20131779.e1713 (2014).","journal-title":"Neurobiol. Aging"},{"key":"55548_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40478-019-0685-7","volume":"7","author":"Q Shao","year":"2019","unstructured":"Shao, Q. et al. C9ORF72 deficiency promotes motor deficits of a C9ALS\/FTD mouse model in a dose-dependent manner. Acta Neuropathol. Commun. 7, 32 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"55548_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41587-020-0456-9","volume":"38","author":"HH Wessels","year":"2020","unstructured":"Wessels, H. H. et al. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat. Biotechnol. 38, 722\u2013727 (2020).","journal-title":"Nat. Biotechnol."},{"key":"55548_CR46","doi-asserted-by":"crossref","unstructured":"Guo, X. et al. Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens. Cell Genom. 1, 100001 (2021).","DOI":"10.1016\/j.xgen.2021.100001"},{"key":"55548_CR47","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1093\/nar\/gkac159","volume":"50","author":"Y Ai","year":"2022","unstructured":"Ai, Y., Liang, D. & Wilusz, J. E. CRISPR\/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 50, e65 (2022).","journal-title":"Nucleic Acids Res."},{"key":"55548_CR48","doi-asserted-by":"publisher","first-page":"111226","DOI":"10.1016\/j.celrep.2022.111226","volume":"40","author":"CP Kelley","year":"2022","unstructured":"Kelley, C. P., Haerle, M. C. & Wang, E. T. Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells. Cell Rep. 40, 111226 (2022).","journal-title":"Cell Rep."},{"key":"55548_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-02860-w","volume":"24","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model. Genome Biol. 24, 20 (2023).","journal-title":"Genome Biol."},{"key":"55548_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s42003-023-04708-2","volume":"6","author":"P Shi","year":"2023","unstructured":"Shi, P. et al. Collateral activity of the CRISPR\/RfxCas13d system in human cells. Commun. Biol. 6, 334 (2023).","journal-title":"Commun. Biol."},{"key":"55548_CR51","doi-asserted-by":"publisher","first-page":"1901299","DOI":"10.1002\/advs.201901299","volume":"6","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv. Sci. 6, 1901299 (2019).","journal-title":"Adv. Sci."},{"key":"55548_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41592-021-01124-4","volume":"18","author":"C Xu","year":"2021","unstructured":"Xu, C. et al. Programmable RNA editing with compact CRISPR\u2013Cas13 systems from uncultivated microbes. Nat. Methods 18, 499\u2013506 (2021).","journal-title":"Nat. Methods"},{"key":"55548_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41587-022-01419-7","volume":"41","author":"H Tong","year":"2023","unstructured":"Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. 41, 108\u2013119 (2023).","journal-title":"Nat. Biotechnol."},{"key":"55548_CR54","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41586-021-03886-5","volume":"597","author":"A \u00d6zcan","year":"2021","unstructured":"\u00d6zcan, A. et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. Nature 597, 720\u2013725 (2021).","journal-title":"Nature"},{"key":"55548_CR55","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00401-014-1286-y","volume":"128","author":"EY Liu","year":"2014","unstructured":"Liu, E. Y. et al. C9ORF72 hypermethylation protects against repeat expansion-associated pathology in ALS\/FTD. Acta Neuropathol. 128, 525\u2013541 (2014).","journal-title":"Acta Neuropathol."},{"key":"55548_CR56","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.neuron.2015.10.027","volume":"88","author":"JG O\u2019Rourke","year":"2015","unstructured":"O\u2019Rourke, J. G. et al. C9ORF72 BAC transgenic mice display typical pathologic features of ALS\/FTD. Neuron 88, 892\u2013901 (2015).","journal-title":"Neuron"},{"key":"55548_CR57","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.neuron.2015.11.018","volume":"88","author":"OM Peters","year":"2015","unstructured":"Peters, O. M. et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88, 902\u2013909 (2015).","journal-title":"Neuron"},{"key":"55548_CR58","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"55548_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain. Mol. Ther. Methods Clin. Dev. 19, 447\u2013458 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"55548_CR60","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1242\/jcs.057075","volume":"122","author":"C Ostlund","year":"2009","unstructured":"Ostlund, C. et al. Dynamics and molecular interactions of linker of nucleoskeleton and cytoskeleton (LINC) complex proteins. J. Cell Sci. 122, 4099\u20134108 (2009).","journal-title":"J. Cell Sci."},{"key":"55548_CR61","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1016\/j.ymthe.2022.08.008","volume":"30","author":"CKW Lim","year":"2022","unstructured":"Lim, C. K. W. et al. CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes. Mol. Ther. 30, 3619\u20133631 (2022).","journal-title":"Mol. Ther."},{"key":"55548_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nbt.3055","volume":"33","author":"L Swiech","year":"2015","unstructured":"Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102\u2013106 (2015).","journal-title":"Nat. Biotechnol."},{"key":"55548_CR63","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41434-021-00272-8","volume":"30","author":"CJ Maturana","year":"2023","unstructured":"Maturana, C. J., Verpeut, J. L., Kooshkbaghi, M. & Engel, E. A. Novel tool to quantify with single-cell resolution the number of incoming AAV genomes co-expressed in the mouse nervous system. Gene Ther. 30, 463\u2013468 (2023).","journal-title":"Gene Ther."},{"key":"55548_CR64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"55548_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2024","unstructured":"Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253\u2013264 (2024).","journal-title":"Nat. Biotechnol."},{"key":"55548_CR66","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/hmg\/ddaa106","volume":"29","author":"NA Ababneh","year":"2020","unstructured":"Ababneh, N. A. et al. Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9ORF72 by CRISPR\/Cas9 genome editing using homology-directed repair. Hum. Mol. Genet. 29, 2200\u20132217 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"55548_CR67","doi-asserted-by":"publisher","first-page":"208ra","DOI":"10.1126\/scitranslmed.3007529","volume":"5","author":"D Sareen","year":"2013","unstructured":"Sareen, D. et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra\u2013149 (2013).","journal-title":"Sci. Transl. Med."},{"key":"55548_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4137\/JCNSD.S18103","volume":"6","author":"J Satoh","year":"2014","unstructured":"Satoh, J. et al. Molecular network analysis suggests a logical hypothesis for the pathological role of C9ORF72 in amyotrophic lateral sclerosis\/frontotemporal dementia. J. Cent. Nerv. Syst. Dis. 6, 69\u201378 (2014).","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"55548_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30387-4","volume":"13","author":"G Krishnan","year":"2022","unstructured":"Krishnan, G. et al. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS\/FTD. Nat. Commun. 13, 2799 (2022).","journal-title":"Nat. Commun."},{"key":"55548_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.15252\/emmm.201707850","volume":"10","author":"R Simone","year":"2018","unstructured":"Simone, R. et al. G-quadruplex-binding small molecules ameliorate C9ORF72 FTD\/ALS pathology in vitro and in vivo. EMBO Mol. Med. 10, 22\u201331 (2018).","journal-title":"EMBO Mol. Med."},{"key":"55548_CR71","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","volume":"11","author":"E Majounie","year":"2012","unstructured":"Majounie, E. et al. Frequency of the C9ORF72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323\u2013330 (2012).","journal-title":"Lancet Neurol."},{"key":"55548_CR72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly, C. J. et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415\u2013428 (2013).","journal-title":"Neuron"},{"key":"55548_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46\u201351 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"55548_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","volume":"36","author":"ME Rook","year":"2022","unstructured":"Rook, M. E. & Southwell, A. L. Antisense oligonucleotide therapy: from design to the huntington disease clinic. BioDrugs 36, 105\u2013119 (2022).","journal-title":"BioDrugs"},{"key":"55548_CR75","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup, A. & Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543\u2013552 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"55548_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1017\/S1355838202020071","volume":"8","author":"Y Zeng","year":"2002","unstructured":"Zeng, Y. & Cullen, B. R. RNA interference in human cells is restricted to the cytoplasm. RNA 8, 855\u2013860 (2002).","journal-title":"RNA"},{"key":"55548_CR77","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.tibtech.2010.07.009","volume":"28","author":"MR Lares","year":"2010","unstructured":"Lares, M. R., Rossi, J. J. & Ouellet, D. L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28, 570\u2013579 (2010).","journal-title":"Trends Biotechnol."},{"key":"55548_CR78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-015-1429-9","volume":"130","author":"J Cooper-Knock","year":"2015","unstructured":"Cooper-Knock, J. et al. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol. 130, 63\u201375 (2015).","journal-title":"Acta Neuropathol."},{"key":"55548_CR79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00401-013-1200-z","volume":"126","author":"S Mizielinska","year":"2013","unstructured":"Mizielinska, S. et al. C9ORF72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845\u2013857 (2013).","journal-title":"Acta Neuropathol."},{"key":"55548_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07746-8","volume":"12","author":"X Piao","year":"2022","unstructured":"Piao, X. et al. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Sci. Rep. 12, 5672 (2022).","journal-title":"Sci. Rep."},{"key":"55548_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33332-7","volume":"13","author":"KE Meijboom","year":"2022","unstructured":"Meijboom, K. E. et al. CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat. Commun. 13, 6286 (2022).","journal-title":"Nat. Commun."},{"key":"55548_CR82","doi-asserted-by":"crossref","unstructured":"Gilbert, J. W. et al. Identification of selective and non-selective C9ORF72 targeting in-vivo active siRNAs. Mol. Ther. Nucleic Acids 35, 102291 (2024).","DOI":"10.1016\/j.omtn.2024.102291"},{"key":"55548_CR83","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/crispr.2020.0018","volume":"3","author":"AB Buchman","year":"2020","unstructured":"Buchman, A. B. et al. Programmable RNA targeting using CasRx in flies. CRISPR J. 3, 164\u2013176 (2020).","journal-title":"CRISPR J."},{"key":"55548_CR84","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omtm.2018.07.006","volume":"10","author":"E Hudry","year":"2018","unstructured":"Hudry, E. et al. Efficient gene transfer to the central nervous system by single-stranded Anc80L65. Mol. Ther. Methods Clin. Dev. 10, 197\u2013209 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"55548_CR85","doi-asserted-by":"crossref","unstructured":"Fomin, V. et al. The C9ORF72 gene, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, encodes a protein that functions in control of endothelin and glutamate signaling. Mol. Cell. Biol. 38, e00155\u201318 (2018).","DOI":"10.1128\/MCB.00155-18"},{"key":"55548_CR86","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.neuron.2021.05.020","volume":"109","author":"D Lall","year":"2021","unstructured":"Lall, D. et al. C9ORF72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron 109, 2275\u20132291.e2278 (2021).","journal-title":"Neuron"},{"key":"55548_CR87","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","volume":"28","author":"CKW Lim","year":"2020","unstructured":"Lim, C. K. W. et al. Treatment of a mouse model of ALS by in vivo base editing. Mol. Ther. 28, 1177\u20131189 (2020).","journal-title":"Mol. Ther."},{"key":"55548_CR88","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","volume":"27","author":"W Duan","year":"2020","unstructured":"Duan, W. et al. The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 27, 157\u2013169 (2020).","journal-title":"Gene Ther."},{"key":"55548_CR89","doi-asserted-by":"publisher","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","volume":"3","author":"T Gaj","year":"2017","unstructured":"Gaj, T. et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 3, eaar3952 (2017).","journal-title":"Sci. Adv."},{"key":"55548_CR90","doi-asserted-by":"publisher","first-page":"e2307814121","DOI":"10.1073\/pnas.2307814121","volume":"121","author":"A Sachdev","year":"2024","unstructured":"Sachdev, A. et al. Reversal of C9orf72 mutation-induced transcriptional dysregulation and pathology in cultured human neurons by allele-specific excision. Proc. Natl Acad. Sci. USA 121, e2307814121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55548_CR91","doi-asserted-by":"publisher","unstructured":"Gaj, T. & Schaffer, D. V. Adeno-associated virus-mediated delivery of CRISPR-Cas systems for genome engineering in mammalian cells. Cold Spring Harb. Protoc. 2016 https:\/\/doi.org\/10.1101\/pdb.prot086868 (2016).","DOI":"10.1101\/pdb.prot086868"},{"key":"55548_CR92","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research 4, 1521\u20131521 (2015).","journal-title":"F1000Research"},{"key":"55548_CR93","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 32, 896\u2013902 (2014).","journal-title":"Nat. Biotechnol."},{"key":"55548_CR94","doi-asserted-by":"publisher","first-page":"W234","DOI":"10.1093\/nar\/gkz240","volume":"47","author":"G Zhou","year":"2019","unstructured":"Zhou, G. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 47, W234\u2013w241 (2019).","journal-title":"Nucleic Acids Res."},{"key":"55548_CR95","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"55548_CR96","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"55548_CR97","doi-asserted-by":"crossref","unstructured":"Berry, G. E. & Tse, L. V. Virus binding and internalization assay for adeno-associated virus. Bio Protoc. 7, e2110\u2013e2110 (2017).","DOI":"10.21769\/BioProtoc.2110"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55548-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:06:52Z","timestamp":1736316412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55548-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55548"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55548-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.12.571328","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.G. and J.P. are inventors on a pending patent application entitled, \u201cTherapeutic gene silencing with CRISPR-Cas13\u201d (18\/576,407) filed by the University of Illinois Urbana-Champaign, which involves the AAV-mediated delivery of RfxCas13d to the brain and spinal cord for gene silencing-based applications. T.G., T.X.M., and C.L. are inventors on a pending provisional patent application entitled, \u201cTargeting the G<sub>4<\/sub>C<sub>2<\/sub> repeat-containing with a high-fidelity CRISPR-Cas13 system improves abnormalities associated with ALS\/FTD\u201d (63\/605,767) filed by the University of Illinois Urbana-Champaign, which involves methods for implementing RfxCas13d for suppressing the repeat RNAs for C9ORF72-linked ALS\/FTD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}